Pathophysiology and effects of endogenous glucocorticoid (GC) excess on skeletal endpoints as well as awareness and management of bone fragility are reviewed. Cushing’s syndrome (CS) increase the risk of fracture affecting prevalently bone quality. Bone antiresorptive agents (SERMs, bisphosphonates and denosumab) as well as teriparatide increase bone mineral density and in some instances reduce fracture risk. Awareness and management of bone health in CS can be improved.

中文翻译：

---

轻度肾上腺库欣综合征和库欣病的骨病

综述了内源性糖皮质激素 (GC) 过量对骨骼终点的病理生理学和影响，以及对骨脆性的认识和管理。库欣综合征 (CS) 会增加骨折的风险，普遍影响骨质量。骨抗吸收剂（SERM、双膦酸盐和狄诺塞麦）以及特立帕肽可增加骨矿物质密度，并在某些情况下降低骨折风险。可以提高对 CS 中骨骼健康的认识和管理。